BAR 704

Drug Profile

BAR 704

Alternative Names: BAR704

Latest Information Update: 08 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bar Pharmaceuticals
  • Class Antifibrotics; Hepatoprotectants
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatic fibrosis; Liver disorders

Most Recent Events

  • 06 May 2017 Preclinical trials in Hepatic fibrosis in Italy (Intraperitoneal) before May 2017
  • 06 May 2017 Preclinical trials in Liver disorders in Italy (Intraperitoneal) before May 2017
  • 06 May 2017 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Liver disorders and Hepatic fibrosis presented at the Digestive Disease Week (DDW-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top